For U.S. Residents Only

Control Disease and Improve Grow-Finish Performance with Denagard® (tiamulin hydrogen fumarate)

Even at subclinical levels, respiratory and enteric diseases can inhibit pig health, limiting performance and profitability. At times of health challenges in a grow-finish unit, Denagard® (tiamulin hydrogen fumarate) plus chlortetracycline (CTC) allows pigs to achieve and maintain better performance by controlling the disease challenges they face.

Control Disease, Increase Performance with Denagard (tiamulin hydrogen fumarate) plus Chlortetracycline (CTC)

Research results have shown that controlling respiratory and enteric disease with an in-feed antimicrobial regimen of Denagard plus CTC resulted in better growth and overall performance in grow-finish pigs.

Studies show:

  • Denagard plus CTC-medicated pigs showed significantly higher daily gain and achieved a significantly higher body weight at the end of the trial period than OTC pigs (+3.9 lbs.) and nonmedicated pigs (+5.7 lbs.)1
  • F:G results indicated a trend toward improvement in the Denagard plus CTC group vs. the OTC pigs (−0.1 pts) and nonmedicated pigs (−0.09 pts)1
  • Denagard plus CTC provided a 4:1 return on investment2

Grow-Finish Charts

Denagard plus CTC offers:

  • Activity from two antibiotics whose individual actions complement one another2
  • Enteric and respiratory disease control*
  • Convenience of feed medication
  • Application for disease control providing cost-effective performance

Quickly Treat Swine Dysentery and Swine Pneumonia with Denagard (tiamulin hydrogen fumarate) Liquid Concentrate 12.5%


Left untreated, respiratory diseases such as pneumonia spread rapidly and can be very contagious, with high morbidity and mortality. Enteric diseases can cause depression, diarrhea and weight loss or weakness in growing pigs. When an outbreak occurs, you need a quick, reliable solution.

Denagard Liquid Concentrate (LC) is the only water-based formulation that treats both swine dysentery and swine pneumonia. Its unique formulation can allow pigs to quickly receive needed medication, even if they’ve gone off feed. Readily absorbed from the gut, it can be found in the blood within 30 minutes after dosing.4

Denagard LC is:

  • Proven effective
  • Rapid treatment
  • Convenient to use
  1. Hammer JM, Dau D. Performance improvement of finishing pigs fed Denagard (tiamulin) plus chlortetracycline in-feed antibiotic vs. oxytetracycline in-feed antibiotic or non-medicated feed, in Proceedings. 21st IPVS Congress 2010;1004.
  2. Hammer JM. 2006 IPVS Satellite Seminar
  3. Hammer JM, Dau D, Jacela J. Effects of Denagard® plus chlortetracycline or oxytetracycline in-feed antimicrobials on growth performance of growing-finishing pigs. Paper presented at: American Association of Swine Veterinarians Annual Meeting; March 2011; Phoenix, AZ.
  4. Anderson MD, Stroh SL. Rogers S. Tiamulin (Denagard) activity in certain swine tissues following oral and intramuscular administration, in Proceedings. American Association of Swine Practitioners Congress 1994;115-117.

* Enteric disease associated with ileitis, swine dysentery, Escherichia coli, Salmonella choleraesuis and/or respiratory disease associated with Pasteurella multocida.

 

Denagard (tiamulin hydrogen fumarate) Medicated Swine Feed

Withdraw medicated feed 2 days before slaughter when using at the dosage rate of 35 g per ton of feed and 7 days before slaughter when using at the dosage rate of 200 g per ton of feed.

Warning: Observe label withdrawal times. Keep out of reach of children. Avoid contact with skin. Direct contact with skin or mucous membranes may cause irritation.

Caution: Do not feed undiluted. Do not use in feeds for animals other than swine. The effects of tiamulin on swine reproductive performance, pregnancy and lactation have not been determined. Swine being treated with Denagard (tiamulin hydrogen fumarate) should not have access to feeds containing polyether ionophores (e.g., lasalocid, monensin, narasin, salinomycin and semduramicin) as adverse reactions may occur. If signs of toxicity occur, discontinue use. See product label for directions for use and additional information.

Denagard (tiamulin hydrogen fumarate) Medicated Swine Feed + Chlortetracycline

Warning: Withdraw medicated feed 2 days before slaughter. Keep out of reach of children. Avoid contact with skin. Direct contact with skin or mucous membranes may cause irritation.

Caution: Use as only source of chlortetracycline. Use as sole source of tiamulin. Do not feed undiluted. Do not use in feeds for animals other than swine. The effects of tiamulin on swine reproductive performance, pregnancy and lactation have not been determined. Swine being treated with Denagard (tiamulin hydrogen fumarate) should not have access to feeds containing polyether ionophores (e.g., lasalocid, monensin, narasin, salinomycin and semduramicin) as adverse reactions may occur. If signs of toxicity occur, discontinue use. See product label for directions for use and additional information.

Denagard (tiamulin hydrogen fumarate) Liquid Concentrate

Warnings: Observe label withdrawal times. Keep out of reach of children. Avoid direct contact with the skin. Direct contact with skin or mucous membranes may cause irritation. Withdraw medicated water 3 days before slaughter after use at 3.5 mg per pound and 7 days before slaughter after use at 10.5 mg per pound.

Caution: For use in animals only – Not for human use. Do not use undiluted. Prepare fresh medicated water daily. Use as the only source of drinking water for 5 days. The effects of tiamulin on swine reproductive performance, pregnancy and lactation have not been determined.

Contraindications: Swine being treated with Denagard (tiamulin) should not have access to feeds containing polyether ionophores (e.g., monensin, lasalocid, narasin, salinomycin and semduramicin) as adverse reactions may occur. See product label for directions for use and additional information.

 

Novartis Animal Health US, Inc.

© Novartis Animal Health US, Inc.
Denagard is a registered trademark of Novartis AG, Basel, Switzerland.